DAPAGLIFLOZIN: COST EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN ECUADOR

被引：0
|
作者：
Elgart, J. F. [1 ]
Prestes, M. [1 ]
Gonzalez, L. [1 ]
Sanchez, Solis C. [2 ]
Acosta, W. [3 ]
Solorzano, J. [4 ]
Gagliardino, J. J. [1 ]
机构：
[1] UNLP, CONICET, Ctr Endocrinol Expt & Aplicada, CENEXA, La Plata, Buenos Aires, Argentina
[2] Univ Hosp, Guayaquil, Ecuador
[3] Hosp Eugenio Espejo, Quito, Ecuador
[4] AstraZeneca CAMCAR MAC, San Jose, Costa Rica
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB33
引用
收藏
页码：A202 / A202
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [2] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Charalampos Tzanetakos
    Nicholas Tentolouris
    Georgia Kourlaba
    Nikos Maniadakis
    [J]. Clinical Drug Investigation, 2016, 36 : 649 - 659
  • [3] Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
    Tzanetakos, Charalampos
    Tentolouris, Nicholas
    Kourlaba, Georgia
    Maniadakis, Nikos
    [J]. CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 649 - 659
  • [4] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    [J]. DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [5] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN THE NETHERLANDS
    van Haalen, H. G. M.
    Pompen, M.
    Bergenheim, K.
    McEwan, P.
    Townsend, R.
    Roudaut, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [7] COST-EFFECTIVENESS OF TYPE 2 DIABETES (T 2DM) TREATMENT WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN IN THE DOMINICAN REPUBLIC AND GUATEMALA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A671 - A672
  • [8] Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population
    Rana Moustafa Al AdAwi
    Zainab Jassim
    Dina Elgaily
    Hani Abdelaziz
    Bhagya Sree
    Mohamed Izham Mohamed Ibrahim
    [J]. Scientific Reports, 9
  • [9] Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population
    Al AdAwi, Rana Moustafa
    Jassim, Zainab
    Elgaily, Dina
    Abdelaziz, Hani
    Sree, Bhagya
    Ibrahim, Mohamed Izham Mohamed
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [10] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Aschner, P.
    Garrido Lecca, S.
    Aiello, E.
    Jimenez, C.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
12345